作者
Yan Nie,John R. Tabor,Jianping Li,Maria Kutera,Jonathan St‐Germain,Ronan P. Hanley,Esther Wolf,Ethan Paulаkonis,Tristan M. G. Kenney,Shili Duan,Suman Shrestha,Dominic D. G. Owens,Ailing Pon,Magdalena M. Szewczyk,Anthony Joseph Lamberto,Michael Menes,Fengling Li,Dalia Baršytė-Lovejoy,Nicholas G. Brown,Anthony M. Barsotti,Andrew W. Stamford,Jon L. Collins,Derek J. Wilson,Brian Raught,Jonathan D. Licht,Lindsey I. James,C.H. Arrowsmith
摘要
Targeted protein degradation (TPD) is an emerging therapeutic strategy that would benefit from new chemical entities with which to recruit a wider variety of ubiquitin E3 ligases to target proteins for proteasomal degradation. Here, we describe a TPD strategy involving the recruitment of FBXO22 to induce degradation of the histone methyltransferase and oncogene NSD2. UNC8732 facilitates FBXO22-mediated degradation of NSD2 in acute lymphoblastic leukemia cells harboring the NSD2 gain of function mutation p.E1099K, resulting in growth suppression, apoptosis, and reversal of drug resistance. The primary amine of UNC8732 is metabolized to an aldehyde species, which engages C326 of FBXO22 in a covalent and reversible manner to recruit the SCF